PTH and Hypocalcemia: Therefore, denosumab strongly inhibits bone resorption, resulting in an increase in calcium release from the bones, causing hypocalcemia, followed by effects on the parathyroid gland, which is the reason for the increased serum PTH level and decreased serum phosphate level.